

MEDIMMUNE INC /DE  
Form 10-Q  
April 28, 2006

## **UNITED STATES**

## **SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D. C. 20549

## **FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES**

**EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2006**

**0-19131**

**(Commission File No.)**

## **MedImmune, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**(State or other jurisdiction of  
incorporation or organization)**

**52-1555759**

**(I. R. S. Employer  
Identification No.)**

**One MedImmune Way, Gaithersburg, MD 20878**

**(Address of principal executive offices) (Zip Code)**

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Registrant's telephone number, including area code ~~(301)~~ **398-0000**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes

No

As of April 20, 2006, 248,753,859 shares of Common Stock, par value \$0.01 per share, were outstanding.

**MEDIMMUNE, INC.**

**Index to Form 10-Q**

Part I	Financial Information	1
Item 1.	Financial Statements	1
	Consolidated Balance Sheets	1
	Consolidated Statements of Operations	2
	Condensed Consolidated Statements of Cash Flows	3
	Notes to Consolidated Financial Statements	4
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17
Item 4.	Controls and Procedures	17
Part II	Other Information	17
Item 1.	Legal Proceedings	17
Item 1A.	Risk Factors	17
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 5.	Other Information	23
Item 6.	Exhibits	24

MedImmune, Synagis, CytoGam, Ethyol, FluMist, NeuTrexin, RespiGam and Vitaxin are registered trademarks of the Company. Numax and Abegrin are trademarks of the Company.

Unless otherwise indicated, this Quarterly Report is current as of March 31, 2006 and the Company undertakes no obligation to update it to reflect events or circumstances after the date of this Quarterly Report or to reflect the occurrence of unanticipated events.

**PART I FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**MEDIMMUNE, INC.**

**CONSOLIDATED BALANCE SHEETS**

(in millions)

**ASSETS:**

Cash and cash equivalents  
Marketable securities  
Trade receivables, net  
Inventory, net  
Deferred tax assets, net  
Other current assets  
Total Current Assets

Marketable securities  
Property and equipment, net  
Deferred tax assets, net  
Intangible assets, net  
Other assets  
Total Assets

**LIABILITIES AND SHAREHOLDERS' EQUITY:**

Accounts payable  
Accrued expenses  
Product royalties payable  
Convertible senior notes  
Other current liabilities  
Total Current Liabilities

Other liabilities  
Total Liabilities

Commitments and Contingencies

**SHAREHOLDERS' EQUITY:**

Preferred stock, \$.01 par value; 5.5 million shares authorized; none issued or outstanding  
Common stock, \$.01 par value; 420.0 million shares authorized; 255.5 million shares issued at March 31, 2006 and 255.5 million shares issued at December 31, 2005  
Paid-in capital  
Accumulated deficit  
Accumulated other comprehensive income

Less: Treasury stock at cost; 6.7 million shares at March 31, 2006 and 8.5 million shares at December 31, 2005

Total Shareholders' Equity  
Total Liabilities and Shareholders' Equity

The accompanying notes are an integral part of these financial statements.

1

**MEDIMMUNE, INC.****CONSOLIDATED STATEMENTS OF OPERATIONS****(Unaudited)**

(in millions, except per share data)

	<b>Three months ended</b>	
	<b>March 31,</b>	
	<b>2006</b>	<b>2005</b>
Revenues:		
Product sales	\$ 491.6	\$ 508.7
Other revenue	6.4	1.1
Total revenues	498.0	509.8
Costs and expenses:		
Cost of sales	123.1	119.8
Research and development	87.9	69.3
Selling, general and administrative	211.9	157.5
Other operating expenses	2.7	2.6
Total expenses	425.6	349.2
Operating income	72.4	160.6
Interest income	15.7	16.7
Interest expense	(2.7)	(2.0)
Gain (loss) on investment activities	(0.8)	0.3
Earnings before income taxes	84.6	175.6
Income tax provision	37.6	61.5
Net earnings	\$ 47.0	\$ 114.1
Basic earnings per share	\$ 0.19	\$ 0.46
Shares used in calculation of basic earnings per share	247.9	248.1
Diluted earnings per share	\$ 0.18	\$ 0.45
Shares used in calculation of diluted earnings per share	260.0	257.2

The accompanying notes are an integral part of these financial statements.

## MEDIMMUNE, INC.

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)  
(in millions)

	<b>Three months ended</b>	
	<b>March 31,</b>	
	<b>2006</b>	<b>2005</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net earnings	\$ 47.0	\$ 114.1
Adjustment to reconcile net earnings to net cash provided by operating activities:		
Share-based compensation expense	9.7	-
Deferred taxes	32.6	61.4
Depreciation and amortization	52.9	8.2
Amortization of premium on marketable securities	3.2	3.9
Realized loss (gain) on investments	0.8	(0.3)
Losses on write downs of inventory	8.9	4.6
Increase in sales allowances	24.2	37.1
Other, net	1.8	1.0
Other changes in assets and liabilities	(19.0)	10.0
Net cash provided by operating activities	162.1	240.0
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Increase in marketable securities, net	(178.9)	(61.7)
Capital expenditures	(28.2)	(14.5)
Minority interest investments	(2.9)	(1.3)
Net cash used in investing activities	(210.0)	(77.5)
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from issuance of common stock	40.7	1.9
Tax benefits from share-based compensation	1.9	-
Share repurchases	-	(17.4)
Repayments on long-term obligations	(0.2)	(0.2)
Net cash provided by (used in) financing activities	42.4	(15.7)
Effect of exchange rate changes on cash	0.1	-
Net (decrease) increase in cash and cash equivalents	(5.4)	146.8
Cash and cash equivalents at beginning of period	153.4	171.3
Cash and cash equivalents at end of period	\$ 148.0	\$ 318.1

The accompanying notes are an integral part of these financial statements.





**MEDIMMUNE, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

**1. Organization**

MedImmune, Inc., a Delaware corporation (together with its subsidiaries, the Company), is a biotechnology company headquartered in Gaithersburg, Maryland. The Company is committed to advancing science to develop better medicines that help people live healthier, longer and more satisfying lives. The Company currently focuses its efforts on using biotechnology to produce innovative products for prevention and treatment in the therapeutic areas of infectious disease, cancer and inflammatory disease. The Company's scientific expertise is largely in the areas of monoclonal antibodies and vaccines. The Company markets four products, Synagis, FluMist, Ethyol and CytoGam, and has a diverse pipeline of development-stage products.

**2. Summary of Significant Accounting Policies**

*General*

The financial information presented as of and for the three months ended March 31, 2006 (Q1 2006) and for the three months ended March 31, 2005 (Q1 2005) is unaudited. In the opinion of the Company's management, the financial information presented herein contains all adjustments necessary for a fair presentation of results for the interim periods presented. The Company's operations and financial results are highly seasonal. Interim results are not necessarily indicative of results for an entire year or for any subsequent interim period. These consolidated financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2005. The December 31, 2005 consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

*Seasonality*

The Company's largest revenue-generating product, Synagis, is used to prevent respiratory syncytial virus (RSV) disease in high-risk infants. RSV is most prevalent in the winter months in the Northern Hemisphere. Because of the seasonal nature of RSV, limited sales, if any, of Synagis are expected in the second and third quarters of any calendar year, causing financial results to vary significantly from quarter to quarter.

FluMist is a nasally delivered live, attenuated vaccine used to help prevent influenza in healthy individuals age 5 to 49. As influenza is most prevalent in the fall and winter months in the Northern Hemisphere, the majority of FluMist sales are expected to occur during the second half of any calendar year, causing financial results to vary significantly from quarter to quarter.

*Intangible Assets*

## Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Management assesses the intangible asset associated with the reacquisition of the U.S. co-promotion rights for Synagis for impairment on a periodic basis. Total future projected domestic sales of Synagis through 2009, used as the basis for amortization of the related intangible asset, are evaluated in conjunction with the annual long range planning process. Should the total of incremental payments, a portion of which are variable based on actual sales, made to Abbott in connection with the reacquisition of the U.S. co-promotion rights for Synagis are ultimately less than the amount of the associated liability recorded, the amount of the intangible asset will be adjusted accordingly.

### *New Accounting Pronouncements*

In December 2004, the Financial Accounting Standards Board ( FASB ) issued SFAS 123R, a revision of SFAS 123, Share-based Payments. SFAS 123R requires public companies to recognize expense associated with share-based compensation arrangements, including employee stock options, using a fair value-based option pricing model, and eliminates the alternative to use the intrinsic value method of accounting for share-based payments under Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees ( APB 25 ). SFAS 123R is effective for the Company s fiscal year beginning January 1, 2006. Adoption of the expense provisions of the statement has a material impact on the Company s results of operations. The Company has adopted SFAS 123R using the modified prospective transition method. Under this method, compensation expense is reflected in the financial statements beginning January 1, 2006 with no restatement of prior periods. As such, compensation expense is recognized for awards that are granted, modified, repurchased or cancelled on or after January 1, 2006 as well as for the portion of awards previously granted that have not vested as of January 1, 2006. The Company has implemented the straight-line expense attribution method, whereas the Company s previous expense attribution method was the graded-vesting method, an accelerated method, described by FASB Interpretation No. 28, Accounting for Stock Appreciation Rights and Other Variable Stock Option or Award Plans ( FIN 28 ).

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

The following table illustrates the effect on net earnings and earnings per share if the Company had applied the fair value recognition provisions to share-based employee compensation in Q1 2005 (in millions, except per share data):

	<b>Q1 2005</b>
Net earnings, as reported	\$ 114.1
Add:	
share-based employee compensation expense included in historical results for the vesting of stock options assumed in conjunction with the Company's acquisition of Aviron in January 2002, calculated in accordance with FIN 44, Accounting for Certain Transactions Involving Stock Compensation-an Interpretation of APB 25, net of related tax effect	0.1
Deduct:	
share-based employee compensation expense determined under the fair value based method for all awards, net of related tax effect	(12.7)
Pro forma net earnings	\$ 101.5
Basic earnings per share, as reported	\$ 0.46
Basic earnings per share, pro forma	\$ 0.41
Diluted earnings per share, as reported	\$ 0.45
Diluted earnings per share, pro forma	\$ 0.40

Effective January 1, 2005, the Company has estimated the fair value of share-based compensation expense associated with employee stock options using a binomial lattice-based option valuation model. The Company believes that the binomial approach provides a better measure of fair value of employee stock options because it incorporates assumptions about patterns of employee exercises in relation to such considerations as stock price appreciation, post-vesting employment termination behavior, the contractual term of the option and other factors. Prior to 2005, the Company estimated the fair value of employee stock options using the Black-Scholes option pricing model, which does not incorporate such correlation assumptions.

The fair value of employee stock options granted since January 1, 2005 was estimated using a binomial model that uses the weighted-average assumptions shown in the table below. The Company uses historical data to estimate option exercise and employee termination within the binomial model; separate groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. Based on an analysis of economic data that marketplace participants would likely use in determining an exchange price for an option, the Company's weighted-average estimate of expected volatility for Q1 2005 was 32%, reflecting the implied volatility determined from the market prices of traded call options on the Company's stock. The expected life of an option is derived from the output of the binomial model and represents the period of time that options granted are expected to be outstanding; the range given below results from certain groups of employees exhibiting different exercise patterns. The risk-free interest rate is based on the rate currently available for zero-coupon U.S. government issues with a term equal to the contractual life of the option.

<b>Assumptions</b>	<b>Q1 2005</b>
Option pricing model	Binomial
Expected stock price volatility	32 %

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Expected dividend yield	0	%
Expected life of option-years	4.6 to 5.1	
Risk-free interest rate	4.3	%
Weighted average fair value of options granted	\$ 8.27	

### 3. Collaborative Agreements

The Company recorded charges totaling \$0 million and \$2.3 million during Q1 2006 and Q1 2005, respectively, associated with upfront fees and milestone payments under licensing agreements and research collaborations, which are included as a component of research and development expense in the consolidated statements of operations.

### 4. Intangible Assets

Intangible assets are comprised of the following (in millions):

	<b>March 31, 2006</b>	<b>Accumulated</b>	<b>December 31, 2005</b>	<b>Accumulated</b>
	<b>Gross Carrying</b>	<b>Amortization</b>	<b>Gross Carrying</b>	<b>Amortization</b>
	<b>Amount</b>	<b>Amount</b>	<b>Amount</b>	<b>Amount</b>
Promotion rights reacquired from Abbott	\$ 360.4	\$ (84.4)	\$ 360.4	\$ (41.3)
Manufacturing know-how acquired				
from Evans	39.0	(36.8)	39.0	(34.6)
Other intangible assets	0.4	(0.4)	0.4	(0.4)
Total	\$ 399.8	\$ (121.6)	\$ 399.8	\$ (76.3)

The Company recorded an intangible asset of \$360.4 million during the third quarter of 2005 in conjunction with the reacquisition of the co-promotion rights for Synagis in the United States. Amortization of the intangible asset is computed based on projected future sales of Synagis over the expected period of active sales and marketing efforts in the United States, which is projected to continue through the first half of 2009.

Amortization of the Evans intangible asset and other intangible assets is computed on the straight-line method based on the estimated useful lives of the assets. The Evans intangible will be fully amortized in the second quarter of 2006.

Amortization for the Company's intangible assets for Q1 2006 and Q1 2005 was \$45.3 million and \$2.2 million, respectively. The estimated aggregate amortization for the remaining life of the assets is as follows (in millions):

For the nine months ended December 31, 2006	\$ 51.1
For the year ended December 31, 2007	104.3
For the year ended December 31, 2008	90.2
For the year ended December 31, 2009	32.6

\$ 278.2

**5. Inventory**

Inventory, net of valuation reserves, is comprised of the following (in millions):

	<b>March 31, 2006</b>	<b>December 31, 2005</b>
Raw Materials	\$ 16.2	\$ 11.1
Work in Process	38.6	42.4
Finished Goods	15.7	15.9
	<b>\$ 70.5</b>	<b>\$ 69.4</b>

The Company recorded permanent inventory write-downs totaling \$8.9 million and \$4.6 million during Q1 2006 and Q1 2005, respectively, in cost of sales to reflect total FluMist inventories at net realizable value.

**6. Share-based Compensation**

As of March 31, 2006, the Company has a number of share-based compensation plans as described below. The pre-tax compensation cost that has been recognized for those plans was \$9.7 million in Q1 2006 (\$0.4 million to cost of sales, \$3.7 million to research and development, \$5.6 million to selling, general and administrative). The total income tax expense

## Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

recognized in the statement of operations for share-based compensation was \$2.4 million in Q1 2006. Share-based compensation cost capitalized in inventory was \$0.5 million in Q1 2006.

The Company grants stock option incentive awards under certain of the following plans. The 2004 Stock Incentive Plan (the 2004 Plan ) is used prospectively as the primary plan for employee awards.

<b>Plan</b>	<b>Description</b>	<b>Shares Authorized for Option Grants (in millions)</b>
1991 Plan	Provides option incentives to employees, consultants and advisors of the Company	33.0
1999 Plan	Provides option incentives to employees, consultants and advisors of the Company	23.3
2003 Non-Employee Directors Plan	Provides option incentives to non- employee directors	0.8
2004 Plan	Provides option, stock appreciation rights, restricted stock, stock units and/or stock incentive awards to employees, non-employee directors, consultants and advisors of the Company	21.0

The following compensation plans, for which there are options outstanding but no future grants will be made, were acquired by the Company in connection with its acquisitions of U.S. Bioscience, Inc. and Aviron ( Acquired Plans ):

<b>Plan</b>	<b>Description</b>
Non-Executive Plan	Provided option incentives to employees who were not officers or directors of U.S. Bioscience, Inc., consultants and advisors of the company
Non-Employee Directors Plan	Provided option incentives to elected non-employee directors of U.S. Bioscience, Inc.
1996 Equity Incentive Plan	Provided incentive and nonstatutory stock options to employees and consultants of Aviron
1999 Non-Officer Equity Incentive Plan	Provided nonstatutory stock options, stock bonuses, rights to purchase restricted stock, and stock appreciation rights to consultants and employees who were not officers or directors of Aviron

Options under all plans normally vest over a three to five year period and have a maximum term of 10 years. The Company has reserved a total of approximately 15.0 million shares of common stock for issuance under these plans as of March 31, 2006. Related stock option activity is as follows (shares in millions):





Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

	1991, 1999 and 2004 Plan		Non-Employee Directors Plans		Acquired Plans	
	Shares	Price per share(1)	Shares	Price per share(1)	Shares	Price per share(1)
Outstanding, Dec. 31, 2002	24.1	\$ 33.45	0.9	\$ 29.53	3.6	\$ 28.17
Granted	5.4	30.18	0.2	35.87		
Exercised	(2.0)	11.61	(0.1)	2.02	(0.7)	21.30
Canceled	(1.4)	41.33			(0.3)	33.98
Outstanding, Dec. 31, 2003	26.1	34.00	1.0	30.52	2.6	29.82
Granted	4.9	23.93	0.2	23.17		
Exercised	(1.0)	9.21	(0.2)	1.31	(0.2)	20.86
Canceled	(2.5)	35.51			(0.3)	32.63
Outstanding, Dec. 31, 2004	27.5	33.12	1.0	33.12	2.1	30.48
Granted	5.0	25.78	0.2	26.71		
Exercised	(1.6)	17.16			(0.4)	21.32
Canceled	(2.4)	33.31			(0.3)	36.78
Outstanding, Dec. 31, 2005	28.5	32.58	1.2	31.88	1.4	32.06
Granted	3.4	36.69				
Exercised	(1.5)	23.17			(0.2)	26.67
Canceled	(0.6)	31.06				
Outstanding, Mar. 31, 2006	29.8	\$ 33.56	1.2	\$ 32.65	1.2	\$ 32.78

(1) Price per share is the weighted average exercise price.

The following disclosure provides a description of the significant assumptions used during Q1 2006, 2005, 2004 and 2003 to estimate the fair value of the Company's employee stock option awards.

Q1 2006 and 2005 - The fair value of employee stock options granted during Q1 2006 and 2005 was estimated using a binomial model that uses the weighted-average assumptions shown in the table below. The Company uses historical data to estimate option exercise and employee termination within the binomial model; separate groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. Based on an analysis of economic data that marketplace participants would likely use in determining an exchange price for an option, the Company's weighted average estimate of expected volatility for Q1 2006 and 2005 reflects the implied volatility determined from the market prices of traded call options on the Company's stock. The expected life of an option is derived from the output of the binomial model and represents the period of time that options granted are expected to be outstanding; the range given below results from certain groups of employees exhibiting different exercise patterns. The risk-free interest rate is based on the rate currently available for zero-coupon U.S. government issues with a term equal to the contractual life of the option.

	Q1 2006		2005	
	Binomial	%	Binomial	%
Option pricing model	31	%	32	%
Expected stock price volatility	0	%	0	%
Expected dividend yield	4.3 to 4.8		4.3 to 5.4	
Expected life of option-years	4.6	%	4.3	%
Risk-free interest rate	\$ 12.46		\$ 8.94	
Weighted average fair value of options granted				

2004 and 2003- The fair value of employee stock options granted during 2004 and 2003 was estimated using a Black-Scholes model that uses the weighted-average assumptions shown in the table below. The expected life of an option was derived from historical stock option exercise experience. The risk-free interest rate was based on the rate currently available for zero-coupon U.S. government issues with a term equal to the expected life of the option.

2004

2003

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Option pricing model	Black-Scholes	Black-Scholes
Expected stock price volatility	49 %	51 %
Expected dividend yield	0 %	0 %
Expected life of option-years	5.0	5.0
Risk-free interest rate	3.4 %	3.3 %
Weighted average fair value of options granted	\$ 11.20	\$ 16.55

8

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Additional information related to the plans as of March 31, 2006 is as follows (shares in millions):

Range of exercise prices	Options Outstanding			Options Exercisable		
	Options Outstanding	Remaining contractual life (yrs)	Wtd. Avg.	Options Exercisable	Wtd. Avg. Ex. Price	Wtd. Avg. Ex. Price
\$ 0.01 \$10.00	1.6	1.6	\$ 6.52	1.6	\$ 6.52	\$ 6.52
\$10.01 \$20.00	1.6	3.0	\$ 18.23	1.6	\$ 18.23	\$ 18.23
\$20.01 \$30.00	12.9	7.4	\$ 25.59	6.7	\$ 26.15	\$ 26.15
\$30.01 \$40.00	8.7	7.2	\$ 36.42	4.2	\$ 36.96	\$ 36.96
\$40.01 \$50.00	3.4	5.1	\$ 42.49	3.4	\$ 42.49	\$ 42.49
\$50.01 \$60.00	0.4	3.7	\$ 56.74	0.4	\$ 56.74	\$ 56.74
\$60.01 \$70.00	3.3	3.3	\$ 60.87	3.3	\$ 60.87	\$ 60.87
\$70.01 \$80.00	0.3	4.4	\$ 72.24	0.3	\$ 72.24	\$ 72.24
	32.2	6.1	\$ 33.50	21.5	\$ 35.43	\$ 35.43

The total intrinsic value of options exercised during Q1 2006 and the years ended December 31, 2005, 2004 and 2003 was \$19.8 million, \$24.5 million, \$15.5 million and \$49.3 million, respectively. The total intrinsic value of options outstanding and options exercisable, using the weighted average exercise price, at March 31, 2006 was \$99.4 million and \$24.8 million, respectively. The weighted average remaining contractual life of options exercisable was 4.8 years.

A summary of the status of the Company's nonvested shares as of March 31, 2006 and changes during Q1 2006 is presented below (shares in millions):

Nonvested Shares	1991, 1999 and 2004 Plans		Non-Employee Directors Plans	
	Shares	Wtd. Avg. Grant-Date Fair Value	Shares	Wtd. Avg. Grant-Date Fair Value
Nonvested, December 31, 2005	8.1	\$ 10.99	0.5	\$ 11.92
Granted	3.4	12.46	-	-
Vested	(1.0)	13.14	-	-
Forfeited	(0.3)	11.20	-	-
Nonvested, March 31, 2006	10.2	11.26	0.5	11.76

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

As of March 31, 2006, there was approximately \$66.2 million of total unrecognized compensation cost related to nonvested employee stock option awards. That cost is expected to be recognized as follows: \$24.9 million in the remainder of 2006, \$19.3 million in 2007, \$12.3 million in 2008, \$8.7 million in 2009 and \$1.0 million in 2010.

The total fair value of shares vested during Q1 2006 and the year ended December 31, 2005, was \$13.5 million and \$70.1 million, respectively.

A summary of the stock options vested and expected to vest as of March 31, 2006 is presented below (shares and intrinsic value in millions):

	<b>Shares</b>	<b>Wtd. Avg. Ex. Price</b>	<b>Wtd. Avg. remaining contractual life (yrs)</b>	<b>Aggregate Intrinsic Value</b>
1991, 1999 and 2004 Plans	27.9	\$ 33.84	6.0	\$ 76.4
Non-Employee Directors Plans	1.2	32.65	6.4	4.7
Acquired Plans	1.2	32.78	3.9	4.5

In June 2001, the Company introduced an employee stock purchase plan under which 3.0 million shares of common stock were reserved for issuance. Eligible employees may purchase a limited number of shares of the Company's common stock at 85% of the market value at plan-defined dates. Employees purchased 0.3 million shares, 0.2 million shares and 0.2 million shares, for \$5.6 million, \$4.6 million and \$4.8 million, during 2005, 2004 and 2003 respectively, under the plan. Expense recognized in Q1 2006 determined using the Black-Scholes model was \$0.5 million.

In connection with the acquisition of Aviron in January 2002, the Company assumed warrants expiring June 2008 to purchase 5.1 million shares of common stock at a price of \$55.13 per share.

## 7. Earnings per Share

The following is a reconciliation of the numerators and denominators of the diluted EPS computation (in millions):

	<b>Q1 2006</b>	<b>Q1 2005</b>
Numerator:		
Net earnings for basic EPS	\$ 47.0	\$ 114.1
Adjustments for interest expense on 1% Convertible Senior Notes, net of tax (1)	0.5	0.6
Earnings for diluted EPS	\$ 47.5	\$ 114.7
Denominator:		
Weighted average shares for basic EPS	247.9	248.1
Effect of dilutive securities:		
Stock options and warrants	4.8	1.8
1% Convertible Senior Notes (1)	7.3	7.3
Weighted average shares for diluted EPS	260.0	257.2
Basic earnings per share	\$ 0.19	\$ 0.46
Diluted earnings per share	\$ 0.18	\$ 0.45

(1) EITF Issue No. 04-8, The Effect of Contingently Convertible Debt on Diluted Earnings per Share, which became effective during the fourth quarter of 2004, requires that all contingently convertible debt instruments be included in diluted earnings per share using the if-converted method, regardless if the market price trigger (or other contingent feature) has been met. Under the provisions of EITF 04-8, the Company's 1% Convertible Senior Notes, which represent 7.3 million potential shares of common stock, are included in the calculation of diluted earnings per share using the if-converted method whether or not the contingent requirements have been met for conversion to common stock, unless the effect is anti-dilutive.

If option exercise prices are greater than the average market price of the Company's common stock for the period presented, the effect of including such options in the earnings per share calculation is anti-dilutive. Options to purchase 14.9 million and 21.3 million shares of common stock at prices ranging from \$35.10 to \$83.25 per share and \$24.20 to \$83.25 per share, were outstanding as of March 31, 2006 and March 31, 2005, respectively, but were not included in the computation of diluted earnings per share because the exercise price of the options exceeded the average market price.

**8. Income Taxes**

The Company's effective tax rate was 44% for Q1 2006 compared to an effective tax rate of 35% for Q1 2005. The increase in the effective tax rate for Q1 2006 was attributable to the impact of share-based compensation, increased state taxes and the absence of certain federal tax credits associated with research and experimentation activities.

**9. Comprehensive Income**

	<b>Q1 2006</b>	<b>Q1 2005</b>
Net earnings	\$ 47.0	\$ 114.1
Change in foreign currency translations adjustment	0.1	(0.4)
Change in unrealized gain (loss) on investments, net of tax	(7.5)	(17.9)
Comprehensive income	\$ 39.6	\$ 95.8

**10. Shareholders Equity**

During Q1 2006, the Company did not repurchase any shares of common stock under the stock repurchase program. During Q1 2005, the Company repurchased approximately 0.7 million shares of common stock under the stock repurchase program at a cost of \$17.4 million, or an average cost of \$24.53 per share. The Company is holding repurchased shares as treasury shares and is using them for general corporate purposes, including but not limited to issuance upon exercise of outstanding stock options and acquisition-related transactions.

**11. Convertible Senior Notes**

The holders of the Company's 1% convertible senior notes may require the Company to redeem the notes on July 15, 2006, as provided for under the notes indenture. If the holders exercise their right to require the Company to purchase all or a portion of their notes in July 2006, the Company will be required to purchase the notes for cash at 100% of the principal amount of the notes, plus any accrued and unpaid interest, contingent interest, if any, and liquidated damages, if any. As such, the aggregate principal amount of the notes of \$500.0 million is classified as a current liability within the consolidated balance sheet.

**12. Legal Proceedings**

The Company's material legal proceedings are described in Note 18 to the consolidated financial statements included with the Company's Annual Report on Form 10-K for the year ended December 31, 2005. With respect to the other legal proceedings described therein, the following material developments have occurred:

With respect to the lawsuit between Biosynexus, Inc. and the Company, the New York state court hearing the matter issued a ruling granting the preliminary injunction that Biosynexus had been seeking pending trial. As a result, the Company is no longer continuing to operate under the agreement in question to develop monoclonal antibodies for infections and diseases caused by staphylococcal bacteria. The litigation is now in the discovery phase and the Company is concurrently appealing the preliminary injunction ruling.

As more fully described in the Company's report on Form 10-K for the year ended December 31, 2005, the Company is a party to a number of city, state and county lawsuits related to the alleged manipulation of average wholesale price of products to government agencies. The Company estimates the range of potential pre-tax loss to range from \$0 to \$15 million, exclusive of alleged treble damages, best price related claims and

other asserted state law causes of action. The Company intends to vigorously defend the claims asserted in such complaints.

**13. Subsequent Event**

On April 25, 2006, the Company entered into a \$600.0 million credit facility with a three year term. The credit facility provides for revolving borrowings and letters of credit collateralized by the Company's cash, cash equivalents and marketable securities, which become restricted to the extent the credit facility is utilized.



**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*This Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements regarding future events and future results that are based on current expectations, estimates, forecasts, and the beliefs, assumptions and judgments of our management. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks and uncertainties that are difficult to predict. Readers are referred to the Forward-Looking Statements section in Part I, Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2005 and the Risk Factors section in Part II, Item 1A of this Quarterly Report on Form 10-Q.*

**INTRODUCTION**

MedImmune is committed to advancing science to develop better medicines that help people live healthier, longer and more satisfying lives. We currently focus our efforts on using biotechnology to produce innovative products for prevention and treatment in the therapeutic areas of infectious disease, cancer and inflammatory disease. Our scientific expertise is largely in the areas of monoclonal antibodies and vaccines. We market four products, Synagis, FluMist, Ethyol and CytoGam, and have a diverse pipeline of development-stage products.

**OVERVIEW OF Q1 2006**

Total revenues decreased 2% in Q1 2006 as compared to Q1 2005 as a result of a 2% decline in sales of Synagis. We recorded diluted net earnings of \$0.18 per share in Q1 2006 compared to diluted net earnings per share of \$0.45 in Q1 2005. The decline in net income in Q1 2006 is primarily attributable to a decline in gross profit, increased research and development spending, amortization of the intangible asset resulting from the acquisition of Synagis promotion rights, higher selling, general and administrative expenses associated with the expansion of the pediatric sales force, and share-based compensation expense.

During Q1 2006, we continued dosing for the final season of the pivotal Phase III study of Numax. We recently announced the intent to begin a Phase III study later in 2006 with Abegrin (formerly known as Vitaxin) on patients with metastatic melanoma. Dosing has also begun on a Phase I study for lupus patients on a monoclonal antibody targeting interferon alpha. During Q1 2006, we earned a \$2.5 million milestone related to GSK's European filing for the cervical cancer vaccine. In the second quarter of 2006, we will begin dosing of a safety study of Numax on children with congenital heart disease, and file the final results of the pivotal Phase III CAIV-T (flu vaccine) study with the FDA.

Our cash and marketable securities at March 31, 2006 increased to \$1.6 billion, as compared to \$1.5 billion as of December 31, 2005, as a result of cash generated by operations.

**CRITICAL ACCOUNTING ESTIMATES**

The preparation of consolidated financial statements requires management to make estimates and judgments with respect to the selection and application of accounting policies that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosures of contingent assets and liabilities. We consider an accounting estimate to be critical if the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made and if changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our

## Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

financial condition or results of operations. For additional information regarding our critical accounting estimates, please refer to Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2005. In addition, there are other items within our financial statements that require estimation, but are not deemed critical as defined above. Changes in estimates used in these and other items could have a material impact on our financial statements. The following discussion updates the critical accounting estimates information included in the Form 10-K for the year ended December 31, 2005.

**Inventory** - We capitalize inventory costs associated with certain products prior to regulatory approval and product launch, based on management's judgment of probable future commercial use and net realizable value. We could be required to permanently write down previously capitalized costs related to pre-approval or pre-launch inventory upon a change in such judgment, due to a denial or delay of approval by regulatory bodies, a delay in commercialization, or other potential factors. Conversely, our gross margins may be favorably impacted if some or all of the inventory previously written down becomes available and is used for commercial sale. There are no inventory amounts related to pre-approval or pre-launch products as of March 31, 2006.

We capitalize inventory costs associated with marketed products based on management's judgment of probable future commercial use and net realizable value. We could be required to permanently write down previously capitalized costs related to commercial inventory due to quality issues or other potential factors. Conversely, our gross margins may be favorably impacted if some or all of the inventory previously written down was recovered through further processing or receipt of a specification waiver from regulatory agencies, and becomes available and is used for commercial sale.

We are required to state all inventory at lower of cost or market. In assessing the ultimate realization of inventories, we are required to make judgments as to multiple factors affecting our inventories and compare these with current or committed inventory levels. In the highly regulated industry in which we operate, raw materials, work-in-process and finished goods inventories have expiration dates that must be factored into our judgments about the recoverability of inventory costs. Additionally, if our estimate of a product's demand and pricing is such that we may not fully recover the cost of inventory, we must consider that in our judgments as well. In the context of reflecting inventory at the lower of cost or market, we will record permanent inventory write-downs as soon as a need for such a write-down is determined. Such write-downs in inventory are permanent in nature, and will not be reversed in future periods.

The valuation of FluMist inventories requires a significant amount of judgment for multiple reasons. Specifically, the manufacturing process is complex, in part due to the required annual update of the formulation for recommended influenza strains, and there can be no guarantee that we will be able to continue to successfully manufacture the product.

The annual FluMist production cycle begins in October of the year prior to the influenza season in which the product will be available for consumption. For example, the production cycle for the 2006/2007 season began in October 2005. Our raw materials have expiration dates (dates by which they must be used in the production process) that range from 24 months to 60 months. Our semi-processed raw materials and work-in-process inventory have multiple components, each having different expiration dates that range from nine to 24 months. Raw materials, semi-processed raw materials, work-in-process inventory and semi-finished goods may be carried over to succeeding production seasons under certain conditions. Each season's finished FluMist product has an approved shelf life up to six months.

For all FluMist inventory components on hand as of March 31, 2006, we reviewed the following assumptions to determine the amount of any necessary reserves: expected production levels and estimated cost per dose; sales volume projections that are subject to variability; the expected price to be received for the product and anticipated distribution costs; utilization of semi-finished goods inventory for the succeeding production season; and current information about the influenza strains recommended by the Centers for Disease Control and Prevention for each season's vaccine. The methodology used to calculate adjustments required to value our FluMist inventories as of March 31, 2006 at net realizable value was consistent with the methodology used for our valuations since product approval in June 2003.

The valuation of inventory as of March 31, 2006 is based on sales volume and price estimates for the 2006/2007 season that are largely based on our actual experience for previous seasons and our expectations for the current season. Sales estimates for the 2006/2007 season incorporated into the inventory valuations performed as of March 31, 2006 were reduced from the estimate used for valuation at December 31, 2005, resulting in a permanent write-down of \$7.2 million in Q1 2006.

The table below summarizes the activity within the components of FluMist inventories (in millions):

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

	<b>Gross Inventory</b>	<b>Reserves</b>	<b>Net Inventory</b>
<b><i>FluMist Details</i></b>			
As of December 31, 2005	\$ 56.4	\$ (37.8)	\$ 18.6
Raw materials, net	0.5	0.2	0.7
Cost of goods sold recognized on 2005/2006 inventory	(1.9)	0.6	(1.3)
Production, net	13.7	(8.9)	4.8
Disposals and scrap	(0.1)	0.6	0.5
As of March 31, 2006	\$ 68.6	\$ (45.3)	\$ 23.3

Because finished FluMist product has an approved shelf life up to six months, no finished product for a particular flu season may be sold in a subsequent season. Thus, if our actual sales fall below our projections, we will be required to write off any remaining finished goods inventory balance at the end of the flu season.

For our other products, we periodically assess our inventory balances to determine whether net realizable value is below recorded cost. Factors we consider include expected sales volume, production capacity and expiration dates.

**Intangible Assets** - Management assesses the intangible asset associated with the reacquisition of the U.S. co-promotion rights for Synagis for impairment on a periodic basis, however, no impairments have occurred as of Q1 2006. Further, the total future projected domestic sales of Synagis through 2009, used as the basis for amortization of the related intangible asset, have not been revised based on quarterly sales results through Q1 2006. Management will assess the estimate of total future domestic Synagis sales in conjunction with the annual long range planning process. If the total of incremental payments, a portion of which are variable based on actual sales, made to Abbott in connection with the reacquisition of co-promotion rights are ultimately less than the amount of the associated liability recorded, the amount of the intangible asset will be adjusted accordingly.

## NEW ACCOUNTING STANDARDS

Issued in December 2004, Statement of Financial Accounting Standards No.123R ( SFAS 123R ) requires public companies to recognize expense associated with share-based compensation arrangements, including employee stock options and stock purchase plans, using a fair value-based option pricing model, and eliminates the alternative to use the intrinsic value method of accounting for share-based payments. SFAS 123R is effective for our fiscal year beginning January 1, 2006. Adoption of the expense provisions of SFAS 123R have a material impact on our results of operations. We have applied the modified prospective transition method; accordingly, compensation expense is reflected in the financial statements beginning January 1, 2006 with no restatement of prior periods. Compensation expense is recognized for awards that are granted, modified, repurchased or cancelled on or after January 1, 2006, as well as for the portion of awards previously granted that have not vested as of January 1, 2006. For the adoption of SFAS 123R, we have selected the straight-line expense attribution method, whereas our previous expense attribution method was the graded-vesting method, an accelerated method, described by FIN 28.

Any future changes to our share-based compensation strategy or programs would likely affect the amount of compensation expense recognized under SFAS 123R and the comparability to our prior period footnote disclosures of pro forma net earnings and earnings per share. Share-based compensation expense recognized in Q1 2006 totaled \$9.7 million on a pre-tax basis, \$12.1 million after tax.

## RESULTS OF OPERATIONS

### Q1 2006 compared to Q1 2005

#### Revenues Product Sales

(in millions)	Q1 2006	Q1 2005	Change	
<b>Synagis</b>				
Domestic	\$ 434.5	\$ 439.5	(1)	%
International	28.5	32.1	(11)	%
	463.0	471.6	(2)	%
<b>Ethyol</b>				

Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Domestic	19.4	21.6	(10)	%
International	0.7	1.1	(35)	%
	20.1	22.7	(11)	%
<b>FluMist</b>	1.7	2.8	(39)	%
<b>Other Products</b>	6.8	11.6	(41)	%
<b>Total Product Sales</b>	\$ 491.6	\$ 508.7	(3)	%

*Synagis* - Synagis accounted for approximately 94% and 93% of our product sales in Q1 2006 and Q1 2005, respectively. In Q1 2006, domestic sales of Synagis decreased 1% to \$434.5 million from Q1 2005 sales of \$439.5 million. The decrease in domestic sales was primarily attributable to lower unit volumes resulting from changes in payer guidelines and the distribution network and regional disruptions caused by hurricanes early in the RSV season, offset partially by price increases of approximately 5%.

We record Synagis international product sales based on a portion of Abbott International's (AI) sales price to customers, as defined in our distribution agreement. Our reported international sales of Synagis decreased 11% to \$28.5 million for Q1 2006 as compared to \$32.1 million in Q1 2005. The decrease was primarily attributable to the timing of shipments to AI.

**Ethiol** - Ethiol accounted for approximately 4% of our product sales in Q1 2006 and Q1 2005. Domestic sales of Ethiol decreased 10% to \$19.4 million in Q1 2006, compared to \$21.6 million in Q1 2005. Of the overall decrease, approximately 18 percentage points resulted from a decrease in domestic sales volume offset by an 8% net price increase. International sales of Ethiol decreased 35% to \$0.7 million versus the prior year quarter.

**FluMist** - Our Q1 2006 product sales of FluMist amounted to \$1.7 million. Due to the seasonal nature of influenza, the majority of FluMist sales are expected to occur between September and January. The decrease from Q1 2005 is due to lower unit volumes.

**Other Products** - Sales of other products in Q1 2006, which primarily represents sales of CytoGam and by-products that result from its manufacturing process, were \$6.8 million in Q1 2006 as compared to \$11.6 million in Q1 2005. The decrease was attributable to supply constraints of CytoGam resulting from raw material shortages of plasma and the transition to a new third-party manufacturer.

#### **Revenues - Other Revenues**

Other revenues for Q1 2006 include \$3.5 million of incremental revenue recognized under the amended international distribution agreement with AI, which represents amounts received in excess of estimated fair value for product sales of Synagis. Such excess amounts have been determined using projected reimbursements for the Synagis season, and are recorded in other revenue, as such excess payments are deemed consideration from AI for the rights to distribute Numax outside of the United States. Other revenues also includes a \$2.5 million milestone related to the filing for European approval of a human papillomavirus vaccine to prevent cervical cancer.

#### **Cost of Sales**

Cost of sales was \$123.1 million for Q1 2006 compared to \$119.8 million in Q1 2005. Gross margins on product sales for Q1 2006 and Q1 2005 were 75% and 76%, respectively. FluMist reduced gross margins by two percentage points in Q1 2006 and one percentage point in Q1 2005. Cost of sales in Q1 2006 included \$0.4 million of share-based compensation expense.

#### **Research and Development Expenses**

## Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Research and development expenses increased 27% to \$87.9 million in Q1 2006, compared to \$69.3 million in Q1 2005. The increase in our drug discovery and development expenses is related to a large number of ongoing clinical and preclinical studies, particularly for Numax (the next generation RSV monoclonal antibody), the costs associated with the expansion of infrastructure to support studies related to various in-licensing agreements and collaborations completed in 2004 and 2005, and share-based compensation expense of \$3.7 million for Q1 2006. Q1 2005 expenses include upfront licensing fees and milestones totaling \$2.3 million in connection with in-licensing agreements and collaborations. During Q1 2005, research and development expenses also include approximately \$0.9 million in connection with the technology transfer and transition activities associated with reacquisition of the influenza vaccines franchise from Wyeth.

### **Selling, General and Administrative Expenses**

Selling, general and administrative ( SG&A ) expenses increased 35% to \$211.9 million in Q1 2006 compared to \$157.5 million in Q1 2005. The increase is largely attributable to the amortization expense of \$43.1 million recognized during Q1 2006 associated with the intangible asset for U.S. co-promotion rights for Synagis, and new marketing and medical education programs related to Synagis and FluMist, as well as continuing expansion of the pediatric commercial organization in advance of the assumption of full promotional responsibility for Synagis in the U.S.. SG&A expense in Q1 2006 also includes \$5.6 million of share-based compensation expense.

### **Gain (Loss) on Investment Activities**

We recorded a loss on investment activities of \$0.8 million during Q1 2006, compared to a gain of \$0.3 million during Q1 2005. The loss in Q1 2006 was primarily due to a partial impairment of a non-public equity investment.



## **Taxes**

We recorded income tax expense of \$37.6 million for Q1 2006, resulting in an effective tax rate of 44% for the period. We recorded income tax expense of \$61.5 million for Q1 2005, resulting in an effective rate of 35% for the period. The increase in the effective rate in Q1 2006 was attributable to the impact of share-based compensation, a portion of which is not deductible for income tax purposes, increased state taxes and the absence of certain federal tax credits associated with research and experimentation activities.

Share-based compensation expense is comprised of incentive stock options, non-qualified stock options and the discount on stock purchased by employees. If incentive stock options are exercised and sold or stock purchased by employees through the employee stock purchase plan is sold within one year, becoming non-qualifying dispositions, we will be allowed to recognize tax deductions at that time. Until that time, we must assume that no tax deduction is allowed.

## **Net Income**

The reported net income for Q1 2006 was \$47.0 million, or \$0.19 per share basic and \$0.18 per share diluted, compared to net income for Q1 2005 of \$114.1 million, or \$0.46 per share basic and \$0.45 per share diluted. Shares used in computing basic and diluted earnings per share in Q1 2006 were 247.9 million and 260.0 million, respectively, while shares used in computing basic and diluted earnings per share for Q1 2005 were 248.1 million and 257.2 million, respectively.

We do not believe inflation had a material effect on our financial statements.

## **LIQUIDITY AND CAPITAL RESOURCES**

**Sources and uses of cash** - Cash and marketable securities increased 11% to \$1.6 billion as of March 31, 2006 as compared to \$1.5 billion as of December 31, 2005. Working capital increased to \$70.6 million at March 31, 2006 from \$(111.2) million as of December 31, 2005 primarily due to the cash generated by operations, which was used to purchase additional marketable securities.

### *Operating Activities*

Net cash provided by operating activities was \$162.1 million in Q1 2006 as compared to \$240.0 million in Q1 2005.

### *Investing Activities*

## Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

Cash used for investing activities during Q1 2006 amounted to \$210.0 million, as compared to \$77.5 million during Q1 2005. Cash used for investing activities in Q1 2006 included net additions to our investment portfolio of \$178.9 million; capital expenditures totaling \$28.2 million, primarily for the construction of our new pilot lab and office facility in Gaithersburg, Maryland; and minority interest investments in strategic partners totaling \$2.9 million through our venture capital subsidiary. We expect our capital expenditures for the full year to approximate \$175.0-\$200.0 million.

### *Financing Activities*

Cash provided by financing activities during Q1 2006 amounted to \$42.4 million as compared to cash used of \$15.7 million during Q1 2005. The increase is primarily due to \$40.7 million received upon the exercise of employee stock options in Q1 2006 as compared to \$1.9 million received in Q1 2005. During Q1 2005, we used \$17.4 million in cash to repurchase shares of our common stock as authorized under our share repurchase program; no repurchases were made in Q1 2006.

Our primary source of liquidity is operating cash flow. Management continues to believe that such internally generated cash flow as well as the existing funds and borrowing capacity under our credit facility will be adequate to service our existing debt and other cash requirements. We expend cash to finance our research and development and clinical trial programs; to obtain access to new technologies through collaborative research and development agreements with strategic partners, through our venture capital subsidiary, or through other means; to fund capital projects; and to finance the production of inventories. We currently anticipate that the holders of our 1% convertible senior notes will require us to redeem the notes for cash in July 2006 as provided for under the indenture. We anticipate using a portion of cash and marketable securities on hand and funding from our collateralized revolving credit facility to repay these notes. In April 2006 we entered into a three-year \$600.0 million credit facility that provides for collateralized revolving borrowings and letters of credit. The BBB rating on our outstanding indebtedness, considered to be investment grade, supports our ability to access capital markets. We may raise additional capital in the future to take advantage of favorable conditions in the market or in connection with our development activities.

Our Board of Directors has authorized the repurchase of up to \$500.0 million of our common stock during the period from July 2003 through June 2006 in the open market or in privately negotiated transactions, pursuant to terms management deems appropriate and at such times it may designate. No repurchases were made in Q1 2006; 1.3 million shares were purchased for \$41.8 million during the period April 1, 2006 through April 25, 2006. During Q1 2005, we repurchased approximately 0.7 million shares of common stock under the stock repurchase program at a cost of \$17.4 million, or an average cost of \$24.53 per share. As of April 25, 2006, approximately \$92.4 million of the \$500.0 million originally authorized remained available for additional repurchases of stock. We are holding repurchased shares as treasury shares and are using them for general corporate purposes, including but not limited to acquisition-related transactions and for issuance upon exercise of outstanding stock options.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We believe our primary market risks as of March 31, 2006 continue to be the exposures to loss resulting from changes in interest rates, foreign currency exchange rates, and equity prices. Our market risks at March 31, 2006 have not changed significantly from those discussed in our Annual Report on Form 10-K for the year ended December 31, 2005. For other information regarding our market risk exposure, please refer to Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk of our Annual Report on Form 10-K for the year ended December 31, 2005.

### **ITEM 4. CONTROLS AND PROCEDURES**

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act )) that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer, President and Vice Chairman ( CEO ), and Senior Vice President and Chief Financial Officer ( CFO ), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable, and not absolute, assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Accordingly, no evaluation or implementation of a control system can provide complete assurance that all control issues and all possible instances of fraud have been or will be detected.

As of March 31, 2006, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures, as required by Rule 13a-15(b) promulgated under the Exchange Act. Based upon that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

In addition, our management, with the participation of our CEO and CFO, have determined that there was no change in our internal control over financial reporting that occurred during Q1 2006 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## **PART II - OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

Information with respect to legal proceedings is included in Note 12 of Part I, Item 1 Financial Statements, and is incorporated herein by reference and should be read in conjunction with the related disclosure previously reported in our Annual Report on Form 10-K for the year ended December 31, 2005.

**ITEM 1A. RISK FACTORS**

Our business faces many risks. The risks described below may not be the only risks we face. Additional risks we do not yet know of or we currently believe are immaterial may also impair our business operations. If any of the events or circumstances described in the following risks actually occur, our business, financial condition or results of operations could suffer, and the trading price of our common stock could decline. You should consider the following risks, together with all of the other information in this Quarterly Report on Form 10-Q as read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2005, before deciding to invest in our securities.

**Our revenues are largely dependent on sales of Synagis.**

Sales of Synagis accounted for approximately 87% - 94% of our total product sales in 2005 and Q1 2006 and our revenues will continue to be largely dependent on sales of Synagis for the foreseeable future. Any perceived or actual event or series of events that have a negative effect on sales of Synagis will have a detrimental affect on our financial condition and results of operations. Events which would affect sales of Synagis include, but are not limited to, any product liability claims (whether supported or not), any manufacturing or supply delays, any sudden loss of inventory, any inability to satisfy product demand, any unsuccessful sales, marketing or distribution strategies and any changes in the authorization, policies, or reimbursement rates for Synagis by private or public insurance carriers or programs.

In addition, Synagis is a biological product regulated and approved for marketing in the U.S. by the FDA and any adverse change in the marketing approval or label for Synagis required by the FDA will have a detrimental affect on our business. We have also created an exclusive network for distribution of Synagis in the U.S., which will have the effect of preventing certain entities from obtaining Synagis and may have the effect of limiting patient access to the product, changing the authorization, policies or reimbursement rates for Synagis by private or public insurance carriers or programs, any of which could result in reduced sales.

Outside of the U.S., AI is responsible for the distribution and commercialization of Synagis as well as obtaining and maintaining regulatory approval for commercialization. Accordingly, sales of Synagis outside of the U.S. are not within our direct control and any negative effect on AI's sales of Synagis could affect our revenues related to those sales. In addition, actions of AI related to the regulatory approval or commercialization of Synagis outside of the U.S. could negatively affect our sales of Synagis in the United States.

**The seasonal nature of a significant portion of our business causes significant fluctuations in our quarterly operating results.**

Sales of two of our products, Synagis and FluMist, are seasonal in nature. Synagis sales occur primarily in the first and fourth quarters of the calendar year and FluMist sales occur primarily in the second half of the calendar year. This high concentration of product sales in a portion of the year causes quarter-to-quarter operating results to vary widely and would exaggerate the adverse consequences on our revenues of any manufacturing or supply delays, any sudden loss of inventory, any inability to satisfy product demand, the inability to estimate the effect of returns and rebates, or of any unsuccessful sales or marketing strategies during the applicable sales season. Furthermore, our current product base limits our ability to offset in the second and third quarters any lower-than-expected sales of Synagis during the first and fourth quarters or FluMist during the second half of the year.

**The approval of CAIV-T is critical to the future of our influenza vaccine business.**

FluMist, in its current frozen formulation, has not been commercially successful. We do not expect our influenza vaccine business to contribute meaningfully to our revenues, income or earnings until and unless we are able to obtain regulatory approval of CAIV-T, the next-generation, refrigerator-stable formulation of FluMist, with a broader approved indication. The timing and outcome of obtaining approval from the U.S. Food and Drug Administration and other similar regulatory agencies in other parts of the world is uncertain. There can be no assurance that any such regulatory agency will approve CAIV-T without the need for additional costly and time-intensive measures; without restrictions as to its marketability; on a timely basis consistent with our expectations; or at all.

**Even if CAIV-T is approved, the commercial success of our influenza vaccine business is uncertain and we may not be able to recover the value of our investment.**

Even if CAIV-T is approved, the market for influenza vaccines is competitive and complex. The commercial success of the product will be limited if we cannot successfully manufacture, distribute and sell it in jurisdictions in which it is approved. The marketplace may view our influenza vaccines as competing against the injectable vaccine. FluMist and CAIV-T have a higher cost of manufacturing at their historic and current volumes relative to injectable vaccines. There can be no assurance that demand for our vaccines will support a volume and price that will achieve a profit in accordance with our expectations, or that our revenues for these products will exceed our cost of goods.

The manufacturing process for FluMist and CAIV-T is complex and product supply will be adversely affected if we are unable to perform the annual update of the formulations for new influenza strains, if we encounter contamination or other problems or difficulties in the process, if we are unable to obtain eggs or other materials necessary for their manufacture, if the regulatory authorities do not approve the product for release, if there is a sudden loss of inventory or for other reasons.

Our distribution experience relates primarily to sales to wholesalers and specialty pharmaceutical distributors. We have limited experience in distributing and selling products like influenza vaccines that are generally sold in greater volume and smaller order quantities, so there can be no assurance that our distribution and sales systems have been optimally designed to yield the greatest return.

We have made significant investments in the development and commercialization of live, attenuated intranasal influenza vaccines. In addition to our internal research, development and commercialization activities, these investments also include the research and development conducted by Aviron before our acquisition of that company; the cost of our acquisition of Aviron; the cost of the activities conducted by Wyeth, our former collaboration partner for development, promotion and distribution of these vaccines; the cost of dissolving the collaboration and reacquiring Wyeth's rights to this franchise; and losses incurred in manufacturing and selling FluMist after its launch. Our results of operations would be negatively affected by impairment charges for the write-down of manufacturing and intangible assets related to FluMist and CAIV-T. For various reasons, primarily those set forth above, there can be no assurance that we will be able to recover the value of our investment in the influenza vaccine business.

**Government involvement may limit the commercial success of our influenza vaccine business.**

If an influenza outbreak occurs and is classified as a pandemic or large epidemic by public health authorities, it is possible that one or more government entities may take actions that directly or indirectly have the effect of abrogating some of our rights or opportunities. We have not manufactured a pandemic vaccine to date, but even if we were to do so, the economic value of such a vaccine to the company could be limited. Our primary manufacturing facility for influenza vaccines is in the U.K. and, in an influenza pandemic, the U.K. government may limit our ability to export product outside the United Kingdom.

Various government entities, including the U.S. government, are offering incentives, grants and contracts to encourage additional investment by commercial organizations into preventative and therapeutic agents against influenza, which may have the effect of increasing the number of competitors and/or providing advantages to known competitors. Accordingly, there can be no assurance that we will be able to successfully establish competitive market share for our influenza vaccines.

In addition, current influenza vaccines are trivalent (contain three strains) and are derived from or analogous to two circulating influenza A viral strains and one circulating influenza B viral strain. If the World Health Organization, the U.S. Centers for Disease Control and Prevention or other similar agencies require or recommend changes in influenza vaccines, for example for a monovalent or quadravalent vaccine or for use of a strain that is not currently circulating in the human population, it is uncertain whether we will be able to manufacture such a product at commercially reasonable rates.

**We may not be able to bring our product candidates to market.**

Research and development activities are costly and may not be successful, and there can be no assurance that any of our product candidates, even if they are in or approved to enter Phase 3 clinical trials, will be approved for marketing by the FDA or the equivalent regulatory agency of any other country. A significant portion of our annual operating budget is spent on research, development and clinical activities. Currently, numerous products are being developed that may never reach clinical trials, achieve success in the clinic, be submitted to the appropriate

regulatory authorities for approval, or be approved for marketing or manufacturing by the appropriate regulatory authorities. There can also be no assurance that we will be able to generate additional product candidates for our pipeline, either through internal research and development, or through the in-licensing or acquisition of products or technology. Even if a product candidate is approved for marketing by the applicable regulatory agency, there can be no assurance that we will be able to successfully manufacture the product on a commercial scale or effectively commercialize the product.

**A significant portion of our business is dependent on third parties.**

We license a significant portion of the technology necessary for our business from third parties and rely on third parties for a significant portion of the clinical development, supply of components, manufacturing, distribution, and promotion of our products. The actions of these third parties are outside of our control and the failure of these third parties to act in accordance with their obligations to us would have a material adverse effect on our business. Even if we are legally entitled to damages for a failure of a third party to fulfill its obligations to us, there can be no assurance that such damages will adequately compensate us for indirect or consequential losses such as the damage to a product brand or our reputation. If a third party does not fulfill its obligations to us, we may have to incur substantial additional costs, which could have a material adverse effect on our business.



**Defending product liability claims could be costly and divert focus from our business operations and product recalls may be necessary.**

Our products contain biologically active agents that can alter the physiology of the person using the product. Accordingly, as a developer, tester, manufacturer, marketer and seller of biological products, we may be subject to product liability claims that may be costly to defend, regardless of whether the claims have merit, and may require removal of an approved product from the market. If a claim were to be successful, there is no guarantee that the amount of the claim would not exceed the limit of our insurance coverage and available cash or cash equivalents. Further, a successful claim could reduce revenues related to the product, result in the FDA taking regulatory action (including suspension of product sales for an indefinite period) or result in significant negative publicity for us or damage to our product brand. Any of these occurrences could have a material adverse effect on our business and could result in a clinical trial interruption or cancellation. Additionally, product recalls may be necessary either in connection with product liability claims or for other reasons. Any such recall would adversely affect sales of that product.

**We may not be able to meet the market demand for our products.**

We generally do not have or contract for redundant supply, production, packaging or other resources to manufacture our products. As a result, we are at risk for business interruption if there is any disruption in the manufacturing chain. Difficulties or delays in our or our contractors manufacturing of existing or new products could increase our costs, cause us to lose revenue or market share and damage our reputation. In addition, because our various manufacturing processes and those of our contractors are highly complex and are subject to a lengthy FDA approval process, alternative qualified production capacity may not be available on a timely basis or at all. In particular, the supply of our products is affected by several manufacturing variables, including the number of production runs, production success rate, product yield and the outcome of quality testing. If we are unable to provide an uninterrupted supply of our products to patients our reputation may be negatively affected, which could have a material and adverse effect on our results of operations.

**We may lose product due to difficulties in the manufacturing process.**

Our manufacturing operations expose us to a variety of significant risks, including: product defects; contamination of product or product loss; environmental problems resulting from our production process; sudden loss of inventory and the inability to manufacture products at a cost that is competitive with third party manufacturing operations. Furthermore, we collaborate and have arrangements with other companies related to the manufacture of our products and, accordingly, certain aspects of the manufacturing process are not within our direct control. In addition, we have not produced FluMist for commercial use at higher volumes and may encounter additional unforeseeable risks as we develop additional commercial manufacturing experience with this product.

**Certain developments in the United Kingdom could have an adverse effect on our ability to manufacture our products.**

Our operations in the U.K. expose us to additional business risks, and failure to manage those risks could have a material adverse effect on our ability to manufacture influenza vaccines. In particular, in the event of a regional or global influenza pandemic, our facilities in the U.K. may be subject to government nationalization. In addition, the facilities are unionized and manufacturing may therefore be interrupted due to labor action.

**Contamination of our raw materials could have a material adverse effect on our product sales, financial condition and results of operations.**

As with other biotechnology companies, the manufacture of our products requires raw materials obtained from a variety of sources including but not limited to animal products or by-products. If these raw materials contain contaminants that are not removed by our approved purification processes, it could result in a material adverse effect on our product sales, financial condition and results of operations and might negatively affect our ability to manufacture those products for an indefinite period of time, regardless of whether such contamination has any proven effect on the safety or efficacy of the product.

**Reimbursement by government and third-party payers is critical for the success of our products.**

The cost to individual consumers for purchase of our products can be significant. Accordingly, sales of our products are dependent to a large extent on the insurance reimbursement available for our products. Actions by government and third-party payers to contain or reduce the costs of health care by limiting reimbursement, changing reimbursement calculation methodologies, increasing procedural hurdles to obtain reimbursement or by other means may have a material adverse effect on sales of our products. We fund and accrue for rebates due to government entities subject to reimbursement, primarily

Medicaid payments to state governments. State governments have the ability to collect rebates for prior periods' activity without restriction by statute and accordingly, we may be subject to future rebate claims by entities for product use in the past for which reimbursement was not sought. In addition, there have been numerous proposals in the U.S., both at the state and federal level, as well as in other countries that would, if adopted, affect the reimbursement of our products and could have a material adverse effect on our product sales, results of operations and financial condition.

**We rely upon a limited number of pharmaceutical wholesalers and distributors that could affect the ability to sell our products.**

We rely largely upon specialty pharmaceutical distributors and wholesalers to deliver our currently marketed products to the end users, including physicians, hospitals, and pharmacies. There can be no assurance that these distributors and wholesalers will adequately fulfill the market demand for our products, nor can there be any guarantee that these service providers will remain solvent. Given the high concentration of sales to certain pharmaceutical distributors and wholesalers, we could experience a significant loss if one of our top customers were to declare bankruptcy or otherwise become unable to fulfill its obligations to us.

**Obtaining and maintaining regulatory approvals to develop, manufacture and market our products is costly and time consuming.**

The development, manufacturing and marketing of all of our products are subject to regulatory approval by the FDA in the U.S., as well as similar authorities in other countries. The approval process for each product is lengthy and potentially subject to numerous delays, which generally would not be in our control. There can be no assurance that any product candidate will be approved for marketing and, if approved, such approval may be limited in scope in such a manner that would harm the product's potential for market success. Even after a product is approved for marketing, it is still subject to continuing regulation. For example, if new adverse event information about a product becomes available from broader use in the market or from additional testing, we may be required by applicable authorities to recall the product or notify health care providers of additional risks associated with use of the product. In addition, our product labeling and marketing activities may be found to be inconsistent with applicable laws and regulations. Even if we have substantially complied with all applicable laws and regulations, the applicable regulatory authorities have the authority to and may revoke or limit approvals or licenses without consulting or obtaining our consent. If we fail to comply with applicable requirements, we may be subject to: fines; seizure of products; total or partial suspension of production; refusal by the applicable authority to approve product license applications; restrictions on our ability to enter into supply contracts; and criminal prosecution. If we are unable to obtain approvals on a timely basis or at all, if the scope of approval is more limited than expected by us or if we are unable to maintain approvals, our ability to successfully market products and to generate revenues will be impaired.

**Patent protection for our products may be inadequate or costly to enforce.**

We may not be able to obtain effective patent protection for our products in development. There are extensive patent filings in the biotechnology industry and the patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions. There can be no assurance that our patent applications will result in patents being issued or that, if issued, such patents will afford protection against competitors with similar technology. Litigation may be necessary to enforce our intellectual property rights. Any such litigation will involve substantial cost and significant diversion of our attention and resources and there can be no assurance that any of our litigation matters will result in an outcome that is beneficial to us. We are also aware that regulatory authorities, including the FDA, are considering whether an abbreviated approval process for so-called generic or follow-on biological products is appropriate. We are uncertain as to when, or if, any such process may be adopted or how such a process would relate to our intellectual property rights, but any such process could have a material effect on the prospects of our products.

**If we fail to obtain and maintain any required intellectual property licenses from third parties, our product development and marketing efforts will be limited.**

Patents have been and will be issued to third parties, and patent applications have been filed by third parties, that claim one or more inventions used in the development, manufacture or use of our products or product candidates. These patents (including any patents issuing from pending patent applications), if valid and enforceable, would preclude our ability to manufacture, use or sell these products unless we obtain a license from the applicable third party. These third parties are not generally required to provide us with a license and, as such, obtaining any such licenses may not be possible or could be costly and impose significant ongoing financial burdens on us. There can be no assurance that a license will be available on terms acceptable to us or at all, which could have a material adverse effect on our business. In addition, there can be no assurance that we will be able to obtain an exclusive license to any such patent, and as a result, the third parties or their sublicensees may be able to produce products that compete with ours. Litigation may be necessary to challenge the

intellectual property rights of third parties and would involve significant cost and significant diversion of management's time and resources. There can be no assurance that any such litigation will result in an outcome that is beneficial to us.

**Technological developments by competitors may render our products obsolete.**

If competitors were to develop superior products or technologies, our products or technologies could be rendered noncompetitive or obsolete. Developments in the biotechnology and pharmaceutical industries are expected to continue at a rapid pace. Success depends upon achieving and maintaining a competitive position in the development of products and technologies. Competition from other biotechnology and pharmaceutical companies can be intense. Many competitors have substantially greater research and development capabilities, marketing, financial and managerial resources and experience in the industry. If a competitor develops a better product or technology, our products or technologies could be rendered obsolete, resulting in decreased product sales and a material adverse effect to our business. Even if a competitor creates a product that is not technologically superior, our products may not be able to compete with such products, decreasing our sales.

**We are subject to numerous complex laws and regulations and compliance with these laws and regulations is costly and time consuming.**

U.S. federal government entities, most significantly the FDA, the U.S. Securities and Exchange Commission, the Internal Revenue Service, the Occupational Safety and Health Administration, the Environmental Protection Agency, the Centers for Medicare and Medicaid Services and the U.S. Department of Veterans Affairs, as well as regulatory authorities in each state and other countries, have each been empowered to administer certain laws and regulations applicable to us. Many of the laws and regulations administered by these agencies are complex and compliance requires substantial time, effort and consultation with our outside advisors. Because of this complexity, there can be no assurance that our efforts will be sufficient to ensure compliance or to ensure that we are in technical compliance with all such laws and regulations at any given time. In addition, we are subject to audit, investigation and litigation by each of these entities to ensure compliance, each of which can also be time consuming, costly, divert the attention of senior management and have a significant effect on our business, even if we are found to have been in compliance or the extent of our non-compliance is deemed immaterial. If we are found to not be in compliance with any of these laws and regulations, we and, in some cases, our officers may be subject to fines, penalties, criminal sanctions and other liability, any of which could have a material adverse effect on our business.

**We cannot control the use of our products.**

The product labeling for each of our products is approved by the FDA and other similar regulatory authorities in other countries and marketed only for certain medical indications, but treating health care practitioners, particularly in the oncology field, are not generally required to restrict prescriptions to the approved label. These practices make it likely that our products are being used for unapproved uses and may subject us to regulatory scrutiny, sanctions or product liability, any of which could have a material adverse effect on our business.

**We may not be able to hire or retain highly qualified personnel or maintain key relationships.**

## Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

The success of our business depends, in large part, on our continued ability to attract and retain highly qualified scientific, manufacturing and sales and marketing personnel, as well as senior management such as Mr. David M. Mott, our Chief Executive Officer, President and Vice Chairman, and Dr. James F. Young, our President, Research and Development. In addition, we rely on our ability to develop and maintain important relationships with leading research institutions and key distributors. Competition for these types of personnel and relationships is intense among pharmaceutical, biopharmaceutical and biotechnology companies, and any obstacles hindering our ability to attract or retain such employees and relationships could have a material effect on our business. We do not maintain or intend to purchase key man life insurance on any of our personnel and, accordingly, our business may be subject to disruption upon the sudden or unexpected loss of a key employee.

**If we fail to manage our growth properly, the business will suffer.**

We have expanded significantly in recent years due to both acquisition and internal growth. To accommodate our rapid growth and compete effectively, we will need to continue to improve our management, operational and financial information systems and controls, generate more revenue to cover a higher level of operating expenses, continue to attract and retain new employees, accurately anticipate demand for products manufactured and expand our manufacturing capacity. This rapid growth and increased scope of operations present risks not previously encountered and could result in substantial unanticipated costs and time delays in product manufacture and development, which could materially and adversely affect the business.

**Fluctuations in our common stock price over time could cause stockholders to lose investment value.**

The market price of our common stock has fluctuated significantly over time, and it is likely that the price will fluctuate in the future. During Q1 2006, the daily closing price of our common stock on the NASDAQ National Market ranged from a high of \$37.38 to a low of \$32.50. During 2005, the daily closing price of our common stock ranged from a high of \$37.06 to a low of \$23.32. Investors and analysts have been, and will continue to be, interested in our reported earnings, as well as how we perform compared to our expectations. Announcements by us or others regarding operating results, existing and future collaborations, results of clinical trials, scientific discoveries, commercial products, patents or proprietary rights or regulatory actions may have a significant effect on the market price of our common stock. In addition, the stock market has experienced price and volume fluctuations that have affected the market price for many biotechnology companies and that have often been unrelated to the operating performance of these companies. These broad market fluctuations may adversely affect the market price of our common stock.

**Changes in foreign currency exchange rates or interest rates could result in losses.**

We have entered into a supplemental manufacturing contract denominated in Euros. Fluctuations in the Euro-U.S. Dollar exchange rate would lead to changes in the U.S. Dollar cost of manufacturing. To reduce the risk of unpredictable changes in these costs, we may, from time to time, enter into forward foreign exchange contracts. However, due to the variability of timing and amount of payments under this contract, the forward foreign exchange contracts may not mitigate the potential adverse effect on our financial results. In addition, expenditures relating to our manufacturing operations in the U.K. and the Netherlands are paid in local currency. We have not hedged our expenditures relating to these manufacturing operations, and therefore foreign currency exchange rate fluctuations may result in increases or decreases in the amount of expenditures recorded. Additionally, certain of our distribution agreements outside the U.S. provide for us to be paid based upon sales in local currency. As a result, changes in foreign currency exchange rates could adversely affect the amount we expect to collect under these agreements. A substantial portion of our current assets is invested in marketable securities, particularly bonds and other fixed income securities, which are subject to fluctuations in value based on interest rates and other factors.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

**(c) Issuer purchases of equity securities(1)**

<b>Period</b>	<b>Total Number of Shares Purchased</b>	<b>Average Price Paid per Share</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</b>	<b>Approximate Dollar Value that May Yet Be Purchased Under the Plans or Programs</b>
January 1, 2006 through January 31, 2006		\$		\$ 134,261,000
February 1, 2006 through February 28, 2006		\$		\$ 134,261,000
March 1, 2006 through March 31, 2006		\$		\$ 134,261,000

(1)

## Edgar Filing: MEDIMMUNE INC /DE - Form 10-Q

The Company's Board of Directors has authorized the repurchase of up to \$500.0 million of the Company's common stock on the open market or in privately negotiated transactions during the period from July 2003 through June 2006.

During the period April 1, 2006 through April 25, 2006, the Company purchased 1.3 million shares of its common stock at a cost of \$41.8 million.

### **ITEM 5. OTHER INFORMATION**

On April 25, 2006, we entered into a \$600.0 million credit facility with a three year term. Wachovia Bank, National Association, and Citibank, N.A., were the joint lead arrangers of the facility, with multiple other banks participating. The credit facility provides for revolving borrowings and letters of credit collateralized by our cash, cash equivalents and marketable securities, which become restricted to the extent the credit facility is utilized.

A copy of the Credit Agreement is attached as Exhibit 10.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.



**ITEM 6. EXHIBITS**

(a) Exhibits:

- 10.1 Credit Agreement dated as of April 25, 2006, by and among MedImmune, the Lenders referred to in the agreement and Wachovia Bank, National Association.
- 31.1 Certification pursuant to 18 USC Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification pursuant to 18 USC Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification pursuant to 18 USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished as permitted by Item 601(b)(32)(ii) of Regulation S-K. This Exhibit 32 is not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not and should not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MEDIMMUNE, INC.**  
(Registrant)

Date: April 26, 2006

/s/ David M. Mott  
David M. Mott  
Chief Executive Officer, President and Vice Chairman  
Principal Executive Officer

Date: April 26, 2006

/s/ Lota S. Zoth  
Lota S. Zoth  
Senior Vice President and Chief Financial Officer  
Principal Financial Officer

Date: April 26, 2006

/s/ Mark E. Spring  
Mark E. Spring  
Vice President, Finance and Controller  
Principal Accounting Officer